Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
When imipenem is dosed at 1 g q8h for serious infections, it is infused over 40-60 min. Its label states that it is indicated for “lower RTI”, an old-fashioned term from the days when bronchitis and pneumonias were still lumped together, CAP was not differentiated from HAP, and HAP and Continue reading Why Did PK/PD Modeling Fail Doripenem in VAP?
If you were developing a new antibiotic with a novel MoA, one that covers most GPC, most GNR, most anaerobes and atypicals, including many MDR pathogens like MRSA, enterococci (both E. faecalis and E. faecium), and one that has also activity against rickettsiae and bioterrorism agents, you would consider it a Continue reading Nominating Thiamphenicol for IDSA’s 10 x ’20 Campaign
When antibiotics change hands, it can be a good thing. Small companies are often desperate to attract a partner with ‘deep pockets’ to help them finance an expensive late phase development but often have to give up control once the honeymoon period is over. Such transitions can bring delays because new Continue reading The Circuitous Route to Phase 3: Another Chapter in the Fitful Development of PTK-0796